NEW YORK – Belgian oncology molecular diagnostics firm Biocartis reported on Thursday that its revenues for the first half of 2020 fell 2 percent year over year.
For the six months ended June 30, Biocartis' total revenues fell to €16.7 million ($19.8 million) from €17.1 million in 2019.